



**TECENTRIQ®**  
atezolizumab 300 mg | 1000 mg  
INJECTION FOR IV USE

 **AVASTIN®**  
bevacizumab



# THE LIVER WEEK 2024

# HCC

# SYMPOSIUM

Roche Luncheon Symposium

---

Exploring the use of Atezolizumab and  
Bevacizumab Therapy in Earlier Stage HCC

---

Date & Time: **June 28, 2024** (Fri), 12:40-13:30

Location : Room 1, Vista I+II, Walkerhill, Seoul

## Roche Luncheon Symposium

# Exploring the use of Atezolizumab and Bevacizumab Therapy in Earlier Stage HCC

We are pleased to invite you to the Roche Luncheon Symposium. This event will delve into the latest advancements and clinical outcomes associated with the earlier than current use of T+A therapy in HCC.



**Chairman**

**Won Young Tak, MD, PhD**

Division of Gastroenterology and Hepatology  
Kyungpook National University College of Medicine, Korea



**Speaker**

**Richard S. Finn, MD**

Department of Medicine, Division of Hematology/Oncology.  
Geffen School of Medicine, UCLA, USA

(주) 한국로슈 서울특별시 서초구 서초대로 411, GT Tower(East)빌딩 17층 (06615)  
Tel 02-3451-3600 <http://www.roche.co.kr>

 **TECENTRIQ**<sup>®</sup>  
atezolizumab

ROCHE | ONCOLOGY  
ANTICPDY 00141101

 **AVASTIN**<sup>®</sup>  
bevacizumab